Welcome to our dedicated page for Merck & Co. news (Ticker: $MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co.'s position in the market.
Merck (MRK) announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA® met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. The trial showed a statistically significant and clinically meaningful improvement in OS compared to placebo, with encouraging results from the progression-free survival, overall response rate, and duration of response data. Merck continues to study KEYTRUDA in gastrointestinal cancers for multiple uses.
Merck (NYSE: MRK) announced positive results from the Phase 3 STRIDE-10 trial evaluating V116, an adult-specific 21-valent pneumococcal conjugate vaccine. The trial showed noninferior immune responses compared to PPSV23 for common serotypes, superior responses for unique serotypes, and a safety profile comparable to PPSV23. The data support V116 as a potential preventative option for invasive pneumococcal disease in adults.